Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSR-042 in Advanced Clear Cell Sarcoma
NCT04274023Phase 2Terminated
- Sponsor
- Italian Sarcoma Group
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in clear cell sarcoma (CCS), sponsored by Italian Sarcoma Group. Primary endpoint: Overall Response Rate at 12 weeks. Started Jan 2024; status: terminated.
02
Drugs
dostarlimab
03
Conditions
clear cell sarcoma (CCS)
Beyond the preview
Go deeper on NCT04274023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274023.